论文部分内容阅读
目的 探讨癌基因mdm2和 p2 1H ras在骨巨细胞瘤 (GCT)中的表达及与GCT病理分级和复发的关系。方法 应用SP免疫组织化学方法检测mdm 2和p2 1H ras在 5 2例GCT(GCT按Jaffe分级 :Ⅰ级 15例、Ⅱ级 2 5例、Ⅲ级 12例 )中的表达。结果 18例mdm 2表达呈阳性 ,阳性率 34.6 % ,7例 p2 1H ras表达呈阳性 ,占 13 .5 %。其阳性表达与病理分级均无显著性相关 (P值分别为 0 .871;0 .6 5 8)。mdm 2和 p2 1H ras在复发和无复发的病例中 ,阳性表达率分别为 6 1.5 %、2 5 .6 %和2 3 .1%、10 .3 %。两者同时阳性表达的有 3例 ,mdm2和p2 1H ras同时过表达与GCT病理分级无显著性相关 (P =0 .75 7) ,而与其复发有显著性相关 (P =0 .0 41)。结论 mdm 2和 p2 1H ras在GCT中的表达与病理分级无关而与其复发有关。
Objective To investigate the expression of oncogenes mdm2 and p2 1H ras in giant cell tumor of bone (GCT) and its relationship with pathological grade and recurrence of GCT. Methods SP immunohistochemical method was used to detect the expression of mdm 2 and p2 1H ras in 52 cases of GCT (GCT according to Jaffe classification: 15 cases of grade I, 25 cases of grade II, and 12 cases of grade III). Results The expression of mdm 2 was positive in 18 cases, the positive rate was 34.6 %. The expression of p2 1H ras was positive in 7 cases, accounting for 13.5%. There was no significant correlation between positive expression and pathological grade (P values were 0.871; 0.65 8). The positive expression rates of mdm 2 and p2 1H ras in relapsed and relapsed cases were 61.5%, 25.6%, 23.1%, and 10.3%, respectively. There were 3 cases with both positive expressions, and the overexpression of mdm2 and p2 1H ras was not significantly associated with the pathological grade of GCT (P=0.75 7), but was significantly correlated with its recurrence (P =0.04). . Conclusions The expression of mdm 2 and p2 1H ras in GCT was not associated with pathological grade but related to its recurrence.